HTG Introduces First Multiplexed Mini-Microarray Solution for Cost Effective Biomarker Discovery and Profiling

(Nanowerk News) HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today introduced the M3(R) Series, the industry's first multiplexed mini-microarray solution for biomarker discovery and gene profiling. The M3 series allows researchers to monitor the behavior of multiple genes in the same sample, simplifying experiments and lowering costs. The platform is based on HTG's proven qNPA ArrayPlate technology, which allows researchers to investigate a customized set of genes with greater precision than traditional microarrays.
"The M3 Series complements traditional whole genome, high density microarray studies by offering a precise look at a set of genes at significantly lower cost and effort than whole genome arrays or qPCR based methods," said HTG president and CEO, TJ Johnson. "HTG's customizable, multiplexed mini-microarrays help scientists validate genes quickly and precisely, which ultimately will lead to better therapies and diagnostics, developed sooner, for improved patient outcomes."
The M3 Series consists of HTG's qCustom™ ArrayPlate, qFix™ Arrays and two chemiluminescent imagers, the Omix™ II Imager, and Capella™ Imager, that are used in conjunction with the customizable multiplexed mini-microarrays. Mini-microarrays can be run in a customer's lab or as a service at HTG. These custom arrays can be designed to detect any transcript. In addition to the custom M3 arrays, HTG is introducing qSelect™ Custom Arrays, off-the-shelf M3 solutions, built from an expanding library of on-demand genes.
The M3 enables researchers to perform multiple runs per sample, improving the statistical reliability of the data. The M3's qNPA platform provides precise, quantitative test results, enabling clients to compress drug discovery and development program timelines, increase program successes and reduce costs.
HTG's qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG's platform is highly flexible and designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at
Source: HTG (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: